Furthermore, the effect of PIOMET on SHBG was further corroborated by our clinical trial, where we observed a significant increase in SHBG in the PIOMET group after 12 weeks of treatment in normal-weight patients with PCOS, which significantly outperformed MET monotherapy. The gene discussed is SHBG; the disease is polycystic ovary syndrome.